SREBF2 and prostate carcinoma: A later study found tocotrienols suppress SREBP-2 activity by degrading mature SREBP-2 in the nucleus via a proteasome-independent mechanism in a human LNCaP-364 androgen-independent prostate cancer cell line (Krycer et al., 2012).